ALACT — Acticor Biotech SA Share Price
0.000.00%
Last trade - 00:00- €44.79m
- €43.88m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 1.62 | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 121.71 | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -292.7% | ||
| Return on Equity | -797.48% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | €m | n/a | n/a | n/a | n/a | n/a | n/a | 60 | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Acticor Biotech SAS is a France-based company. The Company is a clinical stage biopharmaceutical company, a spin-off from INSERM (French National Institute of Health and Medical Research), specialized in the research and development of medicines for the treatment of thrombotic diseases, in particular acute ischemic strokes and pulmonary embolisms. The group has one product in Phase II clinical development (Glenzocimab) and its products in pipeline are ACTIMIS, GARDEN, ACTISAVE and GREEN. Its partnering companies are Ouest Valorisation, Genopole, Medicine and Inserm.
Directors
- Last Annual
- December 31st, 2022
- Last Interim
- June 30th, 2023
- Incorporated
- November 8th, 2013
- Public Since
- November 1st, 2021
- No. of Employees
- 24
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Euronext - Paris
- Shares in Issue
- 12,338,781
- Address
- Hopital Bichat INSERM, PARIS, 75018
- Web
- https://acticor-biotech.com/
- Phone
- Contact
- Gilles Avenard
- Auditors
- Ernst & Young Audit
Upcoming Events for ALACT
Similar to ALACT
Abionyx Pharma SA
Euronext - Paris
Abivax SA
Euronext - Paris
Adocia SA
Euronext - Paris
Biophytis SA
Euronext - Paris
Cellectis SA
Euronext - Paris
FAQ
What is the Acticor Biotech SA share price?
As of Today at 19:00 UTC, shares in Acticor Biotech SA are trading at €3.63. This share price information is delayed by 15 minutes.
How has the Acticor Biotech SA share price performed this year?
Shares in Acticor Biotech SA last closed at €3.63 and the price had moved by -40.88% over the past 365 days. In terms of relative price strength the Acticor Biotech SA share price has underperformed the FTSE Global All Cap Index by -45.47% over the past year.
What are the analyst and broker recommendations for Acticor Biotech SA?
The overall consensus recommendation for Acticor Biotech SA is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Acticor Biotech SA dividend yield?
Acticor Biotech SA does not currently pay a dividend.
Does Acticor Biotech SA pay a dividend?
Acticor Biotech SA does not currently pay a dividend.
When does Acticor Biotech SA next pay dividends?
Acticor Biotech SA does not currently pay a dividend.
How do I buy Acticor Biotech SA shares?
To buy shares in Acticor Biotech SA you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Acticor Biotech SA?
As of the previous close price of €3.63, shares in Acticor Biotech SA had a market capitalisation of €44.79m.
Where are Acticor Biotech SA shares listed?
Here are the trading details for Acticor Biotech SA:
- Country of listing: France
- Exchange: PAR
- Ticker Symbol: ALACT
What kind of share is Acticor Biotech SA?
Based on an overall assessment of its quality, value and momentum Acticor Biotech SA is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Acticor Biotech SA share price forecast for 2024?
The analyst consensus target price for shares in Acticor Biotech SA is €11.30. That is 211.29% above the last closing price of €3.63.
Analysts covering Acticor Biotech SA currently have a consensus Earnings Per Share (EPS) forecast of -€1.07 for the next financial year.
What is the trend in the Acticor Biotech SA share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Acticor Biotech SA. Over the past six months, its share price has underperformed the FTSE Global All Cap Index by -25.63%.
As of the last closing price of €3.63, shares in Acticor Biotech SA were trading -15.15% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Acticor Biotech SA PE Ratio?
The Acticor Biotech SA PE ratio based on its reported earnings over the past 12 months is 1.62. The shares last closed at €3.63.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Acticor Biotech SA?
Acticor Biotech SA's management team is headed by:
- Gilles Avenard - CHM
- Eric Cohen - CFO
- Sophie Lebel-Binay - COO
- Andrea Comenducci - OTH
- Yannick Pletan - OTH